Coste, eficiencia y próximo futuro del desarrollo de nuevos fármacos

Medicina Clinica

Volumn 108, Issue 16, 1997, Pages 621-628

  Dal Ré, Rafael ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG;

ARTICLE; COST; DRUG APPROVAL; ECONOMICS; FORECASTING; RESEARCH;

COSTS AND COST ANALYSIS; DRUG APPROVAL; DRUGS, INVESTIGATIONAL; FORECASTING; RESEARCH;

EID: 0040710726     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (82)

1. Kaitin KI, Bryant NR, Lasagna L. The role of the research-based pharmaceutical industry in medical progress in the United States. J Clin Pharmacol 1993; 33: 412-417.
2. Lis Y, Walker SR. Novel medicines marketed in the UK (1960-87). Br J Clin Pharmacol 1989; 28: 333-343.
3. Halliday RG, Drasdo AL, Lumley CE, Walker RS. A decade of global pharmaceutical R & D expenditure (1981-1990). Pharm Med 1992; 6: 281-296.
4. Alper J. Drug discovery on the assembly line. Science 1994; 264: 1.399-1.401.
5. Monografías de la Real Academia de Farmacia. Diseño de medicamentos. Madrid: Farmaindustria, 1994.
6. Marshall E. Gene therapy's growing pains. Science 1995; 269: 1.050-1.055.
7. Anderson WF. Human gene therapy. Science 1992: 256: 808-813.
8. Leiden JM. Gene therapy, promise, pitfalls, and prognosis. N Engl J Med 1995; 333: 871-873.
9. Spilker B. Multinational drug companies. Issues in drug discovery and development. Nueva York: Raven Press, 1989.
10. Mathieu M. New drug development: a regulatory overview. Cambridge: Parexel International Corporation, 1990.
11. Gansser G, Hueni A. Patent protection for drugs. Basilea: Pharma Information, 1990.
12. Lobato M. El nuevo marco legal de las patentes químicas y farmacéuticas. Madrid: Ed Civitas S.A., 1994.
13. DiMasi JA, Hansen RW, Grabowski HG, Lasagna L. Cost of innovation in the pharmaceutical industry. J Health Econ 1991; 10 107-142.
14. DiMasi JA. Risks, regulation and rewards in new drug development in the United States. Regul Toxicol Pharmacol 1994; 19: 228-235.
15. Grabowski H, Vernon J. A new look at the returns and risks to pharmaceutical R & D. Management Science 1990; 36: 804-821.
16. Towse A. The economics of healthcare: funding and rewarding the usage and the benefits of pharmaceutical. Pharm Med 1995; 9: 129-133.
17. DiMasi JA, Hansen RW, Grabowski HG, Lasagna L. Research and development costs for new drugs by therapeutic category. PharmacoEconomics 1995; 7: 152-169.
18. Drasdo AL, Halliday RG, Lumley CE, Walker SR. The strategy and management of successful global R&D. CMR94-6R. Carshalton: Centre for Medicines Research, 1994.
19. Halliday RG, Walker SR, Lumley CE. R&D philosophy and management in the world's leading pharmaceutical companies. J Pharm Med 1992; 2: 139-154.
20. DiMasi JA, Seibring MA, Lasagna L. New drug development in the United States from 1963 to 1992. Clin Pharmacol Ther 1994; 55: 609-622.
21. Cox JSG, Styles AEJ From lead compound to product. R&D Management 1979; 9: 125-130.
22. DiMasi JA. Success rates for new drugs entering clinical testing in the United States. Clin Pharmacol Ther 1995; 58: 1-14.
23. Pentris RA, Lis Y, Walker SR. Pharmaceutical innovation by seven UK-owned pharmaceutical companies (1964-1984). Br J Clin Pharmacol 1988; 25: 387-396.
24. Tufts Center for the Study of Drug Development Executive summary: white paper of four areas of relevance to new drug development and review in the United States. Drug Infor J 1995; 29: 357-359.
25. Mathieu MP. Parexel's Pharmaceutical R&D statistical sourcebook 1995 & Update. Waltham: Parexel International Corporation, 1995.
26. Maclnnes R, Lumley CE, Walker SR. New chemical entity output of the international pharmaceutical industry from 1970 to 1992. Clin Pharmacol Ther 1994; 56: 339-349.
27. Maclnnes R. Fewer NCEs reach the market in the 1990s. CMR News 1995; 13: 1-2.
28. MacFarlane F. Forty new chemical entities and biologicals first launched in 1994. CMR News 1995; 13: 5-7.
29. New chemical entities and biologicals first launched in 1994 [fe ce errores]. CMR News 1995; 13: 5.
30. Kaitin KI, Manocchia M, Seibring M, Lasagna L. The new drugs approvals of 1990, 1991 and 1992: trends in drug development. J Clin Pharmacol 1994; 34: 120-127.
31. Drummond M. The growing need for economic assessments: implications for pharmaceutical medicine. Pharm Med 1995; 9: 115-122.
32. Sacristán JA, Badía X, Rovira J. Farmacoeconomía: evaluación económica de medicamentos. Madrid: Editores Médicos S.A., 1995.
33. Editorial. Quality of life and clinical trials. Lancet 1995; 346: 1-2.
34. Walley T, Davey P. Pharmacoeconomics: a challenge for clinical pharmacologists. Br J Clin Pharmacol 1995; 40: 199-202.
35. Commonwealth of Australia. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee: including economic analyses, Canberra: Department of Health and Community Services, 1992.
36. Drummond M, Rutten F, Brenna A, Pinto CG, Horisberger B, Jönsson B et al. Economic evaluation of pharmaceutical. A European perspective. PharmacoEconomics 1993; 4: 173-186.
37. Kaitin KI, Richard BW, Lasagna L Trends in drug development: the 1985-86 new drug approvals. J Clin Pharmacol 1987; 27: 542-548.
38. Kaitin KI, DiCerbo PA, Lasagna L. The new drug approvals of 1987, 1988 and 1989: trends in drug development. J Clin Pharmacol 1991; 31: 116-122.
39. Wardell WM. Introduction of new therapeutic drugs in the United States and Great Britain: an international comparison. Clin Pharmacol Ther 1973; 14: 773-790.
40. Wardell WM. The drug lag revisited: comparison by therapeutic area of patterns of drug marketed in the United States and Great Britain from 1972 through 1976. Clin Pharmacol Ther 1978; 24: 499-524.
41. Kaitin KI, Mattison N, Northington FK, Lasagna L. The drug lag: an update of new drug introductions in the United States and in the United Kingdom, 1977 through 1987. Clin Pharmacol Ther 1989; 46: 121-138.
42. Harvey C, Lumley CE, Walker SR. A comparison of the review of a cohort of NCEs by four national regulatory authorities. J Pharm Med 1993; 3: 65-75.
43. Kaitin KI, Brown JS. A drug lag update. Drug Infor J 1995; 29: 361-373.
44. Bakke OM, Manocchia M, De Abajo F, Kaitin KI, Lasagna L. Drug safety discontinuation in the United Kingdom, the United States and Spain from 1974 through 1993: a regulatory perspective. Clin Pharmacol Ther 1995; 58: 108-117.
45. Kaitin KI, Walsh HL. Are initiatives to speed the new drug approval process working? Drug Infor J 1992; 26: 341-349.
46. Food and Drug Administration, Department of Health and Human Services. Code of Federal Regulations 21: Drugs intented to treat life-threatening and severely-debilitating illness (312-E), y Accelerated approval of new drugs for serious or life-threatening illnesses (314-H). Washington DC: US Government printing office, 1993.
47. Koopmans PP. Registration of drugs for treating cancer and HIV infection: a plea to carry out phase 3 trials before admission to the market. Br Med J 1995; 310: 1.305-1.306.
48. Sykes R. Innovation in the pharmaceutical industry. Br Med J 1994; 309: 422-423.
49. Bienz-Tadmor B. Biopharmaceuticals go to market: patterns of worldwide development. Bio/Technology 1993; 11: 168-172.
50. Blumenthal D, Gluck M, Louis KS, Wise D. Industrial support of university research in biotechnology. Science 1986; 231: 242-246.
51. Bienz-Tadmor B, Dicerbo PA, Tadmor G, Lasagna L. Biopharmaceuticals and conventional drugs: clinical success rates. Bio/Technology 1992; 10: 521-525.
52. Bienz-Tadmor B, Brown J. Biopharmaceuticals and conventional drugs: comparing development times. Bio Pharm 1994; 7: 44-49.
53. UK pharma facts and figures-R&D. Script 1993; 1878: 6-7.
54. Italian R&D spending in 1994. Script 1995; 2056/57: 6.
55. French R&D spend static. Scrip 1995; 2047: 4.
56. MacFarlane FG, Kunze ZM, Drasdo AL, Lumley CE, Walker SR. World-wide pharmaceutical research and development expenditure: 1981-91 and current trends J Pharm Med 1995; 5: 17-31.
57. Clinical research disturbing present, uncertain future [editorial]. Lancet 1991; 337: 19-20.
58. Harnessing the profit motive [editorial]. Lancet 1995; 345: 1.189-1.190.
59. Smith R. European research: back to pre-eminence. Br Med J 1992; 304: 899-903.
60. FY 1994 Federal budgets for R&D in biology: NSF, CDC see improvements, but NIH, USDA, DOE fare badly ASM News 1993; 59: 274-276.
61. Rowe PM. USA clinical research must seek new funding sources Lancet 1995; 346: 173.
62. Roche tops 1994 R&D spend rankings. Scrip 1995; 2048: 10.
63. Top pharma companies. Scrip 1995; 2041: 6.
64. Drews J. Innovations in R&D: can the pharmaceutical industry still deliver? CMR News 1995; 13: 2.
65. Bigger companies for better drugs? [editorial]. Lancet 1995; 346: 585-586.
66. Thomas K. How is foreing clinical data used in regulatory submissions? CMR News 1995; 13: 7.
67. Temple R. Trends in pharmaceutical development. Drug Inform J 1993; 27: 355-366.
68. Second International Harmonization Conference. Regul Affairs J 1993; 4: 1.008-1.014.
69. Barber N. International conference on harmonization of technology requirements for registration of pharmaceuticals for human use (ICH). Br J Clin Pharmacol 1994; 37: 401-404.
70. Vozeh S. The international conference on harmonization Eur J Clin Pharmacol 1995; 48: 173-175.
71. ICH3, «global dossier» in sight, but issues remain. Script 1996; 2084: 20-22.
72. Sauer F. General presentation on the European Agency for the evaluation of medicinal products. Londres: EMEA, enero de 1995.
73. Drews J. The impact of cost containment on pharmaceutical research and development. The CMR annual lecture. Carshalton: CMR, 1995.
74. Knowles MR, Hohneker KW, Zhou Z, Olsen JC, Noah TL, Hu PC et al. A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N Engl J Med 1995; 333: 823-831.
75. Mendell JR, Kissel JT, Amato AA, King W, Signore L, Prior TW et al. Myoblast transfer in the treatment of Duchenne's muscular dystrophy. N Engl J Med 1995; 333: 832-838.
76. Atkinson AJ, Becker RE, Galletti PM, Jefferis JE. Wrobleski R. University and pharmaceutical industry cooperation: the need to plan for the future. Clin Pharmacol Ther 1984; 35: 431-437.
77. Erill S. Investigatión académica e investigación industrial en el desarrollo de fármacos. Med Clin (Barc) 1987; 89: 247-249.
78. Posner J. Clinical pharmacology, mutual benefits from greater collaboration between academia and the pharmaceutical industry. Br J Clin Pharmacol 1991; 32: 531-533.
79. Blumenthal D. Academic-industry relationships in life sciences. JAMA 1992; 268: 3.344-3.349.
80. Camí J. Conflicto de intereses e investigación clínica. Med Clin (Barc) 1995; 105: 174-179.
81. Kornberg A. Science in stationary phase. Science 1995; 269: 1.799.
82. Lumley C, Trends in pharmaceutical R&D expenditure 1981-1993. CMR News 1995; 13: 1-3.